Philip J. Stella

7.7k total citations · 1 hit paper
126 papers, 5.6k citations indexed

About

Philip J. Stella is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Philip J. Stella has authored 126 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Oncology, 70 papers in Pulmonary and Respiratory Medicine and 17 papers in Cancer Research. Recurrent topics in Philip J. Stella's work include Lung Cancer Treatments and Mutations (42 papers), Cancer Treatment and Pharmacology (37 papers) and Colorectal Cancer Treatments and Studies (24 papers). Philip J. Stella is often cited by papers focused on Lung Cancer Treatments and Mutations (42 papers), Cancer Treatment and Pharmacology (37 papers) and Colorectal Cancer Treatments and Studies (24 papers). Philip J. Stella collaborates with scholars based in United States, Canada and Belgium. Philip J. Stella's co-authors include Charles L. Loprinzi, Jeff A. Sloan, Allen Lee Cohn, Kendrith M. Rowland, Paul J. Novotny, Aminah Jatoi, Steven E. Schild, Seta Shahin, Edith P. Mitchell and Rafael G. Amado and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Philip J. Stella

124 papers receiving 5.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

2008 644 citations Philip J. Stella et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip J. Stella United States	39	3.3k	2.1k	1.0k	780	757	126	5.6k
Tom R. Fitch United States	34	2.0k 0.6×	1.3k 0.6×	1.2k 1.2×	813 1.0×	652 0.9×	97	4.6k
John W. Kugler United States	32	2.6k 0.8×	1.4k 0.7×	703 0.7×	605 0.8×	490 0.6×	62	4.5k
Óscar Arrieta Mexico	48	3.7k 1.1×	3.2k 1.5×	2.3k 2.3×	1.5k 1.9×	429 0.6×	390	8.4k
James A. Mailliard United States	38	3.8k 1.1×	1.8k 0.8×	772 0.8×	626 0.8×	1.0k 1.4×	92	6.8k
Boštjan Šeruga Canada	34	4.4k 1.3×	1.8k 0.9×	1.2k 1.1×	1.6k 2.1×	455 0.6×	124	7.4k
Emilio Bria Italy	46	4.0k 1.2×	2.8k 1.3×	1.8k 1.8×	1.5k 2.0×	481 0.6×	392	7.1k
Thomas Aparicio France	40	3.6k 1.1×	2.1k 1.0×	716 0.7×	866 1.1×	679 0.9×	254	6.5k
J A Mailliard United States	35	4.6k 1.4×	1.9k 0.9×	721 0.7×	450 0.6×	1.1k 1.4×	60	6.7k
Francesco Cognetti Italy	46	5.0k 1.5×	2.3k 1.1×	2.4k 2.3×	1.7k 2.2×	558 0.7×	221	8.5k
Francesco Perrone Italy	38	3.6k 1.1×	1.8k 0.9×	1.1k 1.1×	870 1.1×	272 0.4×	188	5.9k

Countries citing papers authored by Philip J. Stella

Since Specialization

Citations

This map shows the geographic impact of Philip J. Stella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip J. Stella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip J. Stella more than expected).

Fields of papers citing papers by Philip J. Stella

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip J. Stella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip J. Stella. The network helps show where Philip J. Stella may publish in the future.

Co-authorship network of co-authors of Philip J. Stella

This figure shows the co-authorship network connecting the top 25 collaborators of Philip J. Stella. A scholar is included among the top collaborators of Philip J. Stella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip J. Stella. Philip J. Stella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Borghaei, Hossein, Mary W. Redman, Karen Kelly, et al.. (2020). SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study). Clinical Lung Cancer. 22(3). 178–186. 8 indexed citations

Velcheti, Vamsidhar, Tarek Mekhail, Ticiana Leal, et al.. (2018). Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). Annals of Oncology. 29. viii744–viii744. 47 indexed citations

Laquente, Berta, José A. López-Martín, Donald Richards, et al.. (2017). A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer. 17(1). 137–137. 53 indexed citations

Jatoi, Aminah, Rui Qin, Daniel Satele, et al.. (2016). “Enjoy glass of wine before eating:” a randomized trial to test the orexigenic effects of this advice in advanced cancer patients. Supportive Care in Cancer. 24(9). 3739–3746. 8 indexed citations

Hurwitz, Herbert I., Nikhil Uppal, Stephanie A. Wagner, et al.. (2015). Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. Journal of Clinical Oncology. 33(34). 4039–4047. 237 indexed citations

Molina, Julian R., Nathan R. Foster, Thanyanan Reungwetwattana, et al.. (2014). A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer. 85(2). 245–250. 37 indexed citations

Hurwitz, H., Nikhil Uppal, J. C. Bendell, et al.. (2014). Results from a Phase 2 Study of Ruxolitinib or Placebo with Capecitabine as Second-Line Therapy in Patients with Metastatic Pancreatic Cancer: The Recap Trial. Annals of Oncology. 25. ii115–ii115. 2 indexed citations

Ramnath, Nithya, Stephanie Daignault‐Newton, Grace K. Dy, et al.. (2013). A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 71(5). 1173–1182. 23 indexed citations

Tan, Winston, Jacob B. Allred, Muhammad Salim, et al.. (2012). Phase II Interventional Study (N0337) of Capecitabine in Combination With Vinorelbine and Trastuzumab for First- or Second-Line Treatment of HER2-Positive Metastatic Breast Cancer: A North Central Cancer Treatment Group Trial. Clinical Breast Cancer. 12(2). 81–86. 6 indexed citations

10.

Dy, Grace K., Sumithra J. Mandrekar, Garth D. Nelson, et al.. (2012). A Randomized Phase II Study of Gemcitabine and Carboplatin with or without Cediranib as First-Line Therapy in Advanced Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group Study N0528. Journal of Thoracic Oncology. 8(1). 79–88. 36 indexed citations

11.

Reinholz, Monica M., Kathleen Tenner, David W. Hillman, et al.. (2011). Cytokeratin-19 and Mammaglobin Gene Expression in Circulating Tumor Cells from Metastatic Breast Cancer Patients Enrolled in North Central Cancer Treatment Group Trials, N0234/336/436/437. Clinical Cancer Research. 17(22). 7183–7193. 45 indexed citations

12.

Aisner, Joseph, Judith Manola, Shaker R. Dakhil, Philip J. Stella, & Joan H. Schiller. (2011). Randomized phase II study of vandetanib (V), docetaxel (D), and carboplatin (C) followed by maintenance V or placebo (P) in patients with stage IIIb, IV, or recurrent non-small cell lung cancer (NSCLC): PrECOG PrE0501—Update on maintenance treatment, progression-free survival (PFS), and overall survival (OS).. Journal of Clinical Oncology. 29(15_suppl). 7560–7560. 4 indexed citations

13.

Loprinzi, Charles L., Ernie Balcueva, Heshan Liu, et al.. (2011). A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Pilocarpine for Vaginal Dryness: North Central Cancer Treatment Group Study N04CA. PubMed. 9(3). 105–112. 9 indexed citations

14.

Jatoi, Aminah, Steven E. Schild, Nathan R. Foster, et al.. (2010). A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Annals of Oncology. 21(10). 2040–2044. 40 indexed citations

15.

Jatoi, Aminah, Shaker R. Dakhil, Nathan R. Foster, et al.. (2008). Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B). Journal of Thoracic Oncology. 3(5). 516–520. 26 indexed citations

16.

Halyard, Michele Y., Aminah Jatoi, Jeff A. Sloan, et al.. (2007). Does Zinc Sulfate Prevent Therapy-Induced Taste Alterations in Head and Neck Cancer Patients? Results of Phase III Double-Blind, Placebo-Controlled Trial from the North Central Cancer Treatment Group (N01C4). International Journal of Radiation Oncology*Biology*Physics. 67(5). 1318–1322. 85 indexed citations

17.

Jatoi, Aminah, Philip J. Stella, Nathan R. Foster, et al.. (2006). Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. Annals of Oncology. 17(4). 652–656. 42 indexed citations

18.

Jatoi, Aminah, Shauna L. Hillman, Philip J. Stella, et al.. (2005). Should Elderly Non–Small-Cell Lung Cancer Patients Be Offered Elderly-Specific Trials? Results of a Pooled Analysis From the North Central Cancer Treatment Group. Journal of Clinical Oncology. 23(36). 9113–9119. 100 indexed citations

19.

Perez, Edith A., David W. Hillman, Philip J. Stella, et al.. (2000). A phase II study of paclitaxel plus carboplatin as first‐line chemotherapy for women with metastatic breast carcinoma. Cancer. 88(1). 124–131. 13 indexed citations

20.

Barton, Debra L., Charles L. Loprinzi, Susan K. Quella, et al.. (1998). Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.. Journal of Clinical Oncology. 16(2). 495–500. 288 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact